Eli Lilly and Co. announced plans to streamline a portion of its manufacturing operations in Indianapolis in an effort to align manufacturing capacity and engineering support services with the needs of the business. This streamlining affects sites that manufacture APIs for the insulin products Humalog and Humulin as well as the osteoporosis drug Forteo.     Lilly is offering a voluntary exit program to employees in selected areas, with enhanced financial incentives. This program is expected t...